London-based start-up Lindus Health is using its technology platform and machine learning to manage clinical trials from start to finish. The company aims to speed up approvals and improve the time it takes to get treatments to market. Lindus Health has raised $6m from investors, including PayPal co-founder Peter Thiel, to accelerate its use of machine learning and data science to revolutionise clinical trials. The firm has already delivered more than 80 trials for treatments across the US, UK and Europe. Lindus Health is partnering with global healthcare company Pharmanovia to evaluate the safety and efficacy of a treatment for patients with severe insomnia in a real-world setting, and working with Oto to run a trial evaluating its digital tinnitus solution against in-person therapy.
London-based start-up Lindus Health has secured $6 million in funding from investors, including PayPal co-founder Peter Thiel, to accelerate the use of machine learning and data science in clinical trials. The company aims to revolutionize the process of finding innovative treatments for conditions such as tinnitus, insomnia, and progressive childhood short-sightedness, using their technology platform to manage trials from start to finish. Lindus Health’s pioneering technology speeds up the time it takes to approve treatments and get them to market, with their trials to date having been completed three times more quickly than the old-fashioned industry standard.
The company has also received an Innovate UK Smart Grant worth almost half a million pounds, with their work in machine learning and data science described by UKRI assessors as a “hugely valuable and game-changing project”.
Lindus Health has already delivered more than 80 trials for treatments across the US, UK, and Europe. They are next working with the global healthcare company Pharmanovia to evaluate the safety and efficacy of a treatment for patients with severe insomnia in a real-world setting, using digital technology to find hard-to-reach insomnia patients. They will also be working with Oto to run a trial for 200 people, evaluating their digital tinnitus solution against in-person therapy.
In addition, Lindus Health is partnering with Berlin-based start-up Dopavision to trial the MyopiaX treatment for children affected by progressive short-sightedness. This aims to increase dopamine levels in the retina to slow the progression of the condition.
Lindus Health is also launching a trial aimed at treating and reversing Type 2 Diabetes with George Medicines this year. They are also launching a trial aimed at reducing symptoms of menopause with US-based Bonafide Health (parent company – JDS Therapeutics).
Launched in 2021 by Michael Young and Meri Beckwith, Lindus Health has already worked with 20,000 patients to find new treatments for chronic conditions.
Clinical trials are the biggest bottleneck to improving human health. Lindus Health’s innovative use of machine learning and data science is set to revolutionize the process of finding innovative treatments for a range of conditions. With backing from high-profile investors, including Peter Thiel, and an Innovate UK Smart Grant, Lindus Health is well-positioned to help treatments reach patients more quickly to improve and extend lives.
